Company logo

ANVS - Annovis Bio, Inc.

NYSE -> Healthcare -> Biotechnology
Berwyn, United States
Type: Equity

ANVS price evolution
ANVS
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Current assets
Cash $3.14 $5.75 $6.35 $15.72
Short term investments
Net receivables
Inventory
Total current assets $7.81 $10.21 $10.22 $22.82
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $7.81 $10.21 $10.22 $22.82
Current liabilities
Accounts payable $4.11 $1.29 $1.93 $1.17
Deferred revenue
Short long term debt
Total current liabilities $4.87 $4.28 $3.56 $2.07
Long term debt
Total noncurrent liabilities $6.3 $13.68
Total debt
Total liabilities $11.17 $17.96 $3.56 $2.07
Shareholders' equity
Retained earnings -$111.33 -$110.26 -$88.05 -$73.33
Other shareholder equity
Total shareholder equity -$3.35 -$7.75 $6.66 $20.74
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 30 Jan 2021
Current assets
Cash $5.75 $28.38 $45.69 $8.07
Short term investments
Net receivables
Inventory
Total current assets $10.21 $36.02 $46 $8.12
Long term investments
Property, plant & equipment
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $10.21 $36.02 $46 $8.12
Current liabilities
Accounts payable $1.29 $3.96 $0.69 $0.34
Deferred revenue
Short long term debt
Total current liabilities $4.28 $7.7 $1.51 $0.58
Long term debt
Total noncurrent liabilities $13.68
Total debt
Total liabilities $17.96 $7.7 $1.51 $0.58
Shareholders' equity
Retained earnings -$110.26 -$54.05 -$28.73 -$14.24
Other shareholder equity $0
Total shareholder equity -$7.75 $28.32 $44.49 $7.54
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $6.51 $8.9 $13.84 $8.26
Selling, general & administrative $1.29 $1.54 $1.03 $1.5
Total operating expenses $7.81 $10.44 $14.86 $9.76
Operating income -$7.81 -$10.44 -$14.86 -$9.76
Income from continuing operations
EBIT -$1.07 -$22.21 -$14.72 -$9.54
Income tax expense
Interest expense
Net income
Net income -$1.07 -$22.21 -$14.72 -$9.54
Income (for common shares) -$1.07 -$22.21 -$14.72 -$9.54
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 30 Jan 2021
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $38.79 $16.52 $8.48
Selling, general & administrative $6.24 $9 $6.06
Total operating expenses $45.04 $25.51 $14.54 $6.64
Operating income -$45.04 -$25.51 -$14.54 -$6.64
Income from continuing operations
EBIT -$56.2 -$25.33 -$14.49
Income tax expense
Interest expense
Net income
Net income -$56.2 -$25.33 -$14.49 -$5.46
Income (for common shares) -$56.2 -$25.33 -$14.49
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Net income -$1.07 -$22.21 -$14.72 -$9.54
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $0.36 $0.88 $0.63 $1.57
Total cash flows from operations -$7.03 -$9.36 -$9.37 -$9.61
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $4.42 $8.76 $8.57
Net borrowings
Total cash flows from financing $4.42 $8.76 $8.57
Effect of exchange rate
Change in cash and equivalents -$2.62 -$0.6 -$9.37 -$1.03
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 30 Jan 2021
Net income -$56.2 -$25.33 -$14.49 -$5.46
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation $4.63 $9.15 $4.7
Total cash flows from operations -$39.97 -$17.31 -$9.13 -$3.97
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $17.34 $0 $46.74
Net borrowings
Total cash flows from financing $17.34 $0 $46.74 $12.04
Effect of exchange rate
Change in cash and equivalents -$22.62 -$17.31 $37.61 $8.07
Fundamentals
Market cap $144.36M
Enterprise value $141.22M
Shares outstanding 11.01M
Revenue $0.00
EBITDA -$47.53M
EBIT -$47.53M
Net Income -$47.53M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -3.04
EV/Sales N/A
EV/EBITDA -2.97
EV/EBIT -2.97
P/S ratio N/A
P/B ratio -43.04
Book/Share -0.30
Cash/Share 0.28
EPS -$4.32
ROA -372.37%
ROE -1.17K%
Debt/Equity -2.32
Net debt/EBITDA -0.17
Current ratio 1.60
Quick ratio 1.60